Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.
The catalyst? Macrogenics' shares took flight after the company announced a licensing deal with Incyte Corp. (NASDAQ: INCY) for its programmed cell-death protein 1 (PD-1) inhibitor, MGA012, that's being assessed in four solid tumor types in an early-stage dose-escalation study.
Image source: Getty Images.
Source: Fool.com
Incyte Corp. Stock
€63.22
-0.250%
With 13 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 77 € shows a positive potential of 21.8% compared to the current price of 63.22 € for Incyte Corp..
